vs
CSP INC（CSPI）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是CSP INC的1.6倍（$19.6M vs $12.0M），CSP INC净利率更高（0.8% vs -177.4%，领先178.2%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -23.2%），CSP INC自由现金流更多（$-3.0M vs $-23.1M），过去两年CSP INC的营收复合增速更高（-6.3% vs -12.2%）
CSP Inc.是一家总部位于美国的科技企业，主营网络安全解决方案、托管IT服务、高性能计算系统及专业IT咨询服务，核心客户覆盖北美及部分国际市场的医疗、金融、制造、公共部门等领域的企业。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CSPI vs LAB — 直观对比
营收规模更大
LAB
是对方的1.6倍
$12.0M
营收增速更快
LAB
高出11.7%
-23.2%
净利率更高
CSPI
高出178.2%
-177.4%
自由现金流更多
CSPI
多$20.1M
$-23.1M
两年增速更快
CSPI
近两年复合增速
-12.2%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.0M | $19.6M |
| 净利润 | $91.0K | $-34.7M |
| 毛利率 | 39.3% | 48.5% |
| 营业利润率 | -0.9% | -168.5% |
| 净利率 | 0.8% | -177.4% |
| 营收同比 | -23.2% | -11.5% |
| 净利润同比 | -80.7% | -28.8% |
| 每股收益（稀释后） | $0.01 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSPILAB
| Q4 25 | $12.0M | — | ||
| Q3 25 | $14.5M | $19.6M | ||
| Q2 25 | $15.4M | $21.8M | ||
| Q1 25 | $13.1M | $40.8M | ||
| Q4 24 | $15.7M | — | ||
| Q3 24 | $13.0M | $22.1M | ||
| Q2 24 | $13.1M | $22.5M | ||
| Q1 24 | $13.7M | $45.5M |
净利润CSPILAB
| Q4 25 | $91.0K | — | ||
| Q3 25 | $-191.0K | $-34.7M | ||
| Q2 25 | $-264.0K | $-33.5M | ||
| Q1 25 | $-108.0K | $-26.0M | ||
| Q4 24 | $472.0K | — | ||
| Q3 24 | $-1.7M | $-26.9M | ||
| Q2 24 | $-185.0K | $-45.7M | ||
| Q1 24 | $1.6M | $-32.2M |
毛利率CSPILAB
| Q4 25 | 39.3% | — | ||
| Q3 25 | 36.6% | 48.5% | ||
| Q2 25 | 28.8% | 48.8% | ||
| Q1 25 | 32.0% | 48.4% | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 28.4% | 54.9% | ||
| Q2 24 | 35.0% | 46.1% | ||
| Q1 24 | 47.3% | 53.1% |
营业利润率CSPILAB
| Q4 25 | -0.9% | — | ||
| Q3 25 | -3.7% | -168.5% | ||
| Q2 25 | -7.9% | -118.1% | ||
| Q1 25 | -7.6% | -80.8% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -15.7% | -120.9% | ||
| Q2 24 | -5.5% | -134.5% | ||
| Q1 24 | 9.0% | -132.2% |
净利率CSPILAB
| Q4 25 | 0.8% | — | ||
| Q3 25 | -1.3% | -177.4% | ||
| Q2 25 | -1.7% | -153.7% | ||
| Q1 25 | -0.8% | -63.8% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | -12.7% | -122.0% | ||
| Q2 24 | -1.4% | -203.3% | ||
| Q1 24 | 11.6% | -70.6% |
每股收益（稀释后）CSPILAB
| Q4 25 | $0.01 | — | ||
| Q3 25 | $-0.02 | $-0.09 | ||
| Q2 25 | $-0.03 | $-0.09 | ||
| Q1 25 | $-0.01 | $-0.07 | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $-0.17 | $-0.07 | ||
| Q2 24 | $-0.02 | $-0.12 | ||
| Q1 24 | $0.16 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.9M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $44.8M | $399.7M |
| 总资产 | $69.2M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSPILAB
| Q4 25 | $24.9M | — | ||
| Q3 25 | $27.4M | $129.4M | ||
| Q2 25 | $26.3M | $158.6M | ||
| Q1 25 | $29.5M | $150.9M | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $30.6M | $210.6M | ||
| Q2 24 | $28.9M | $269.8M | ||
| Q1 24 | $27.1M | $287.1M |
总债务CSPILAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益CSPILAB
| Q4 25 | $44.8M | — | ||
| Q3 25 | $44.6M | $399.7M | ||
| Q2 25 | $47.5M | $424.5M | ||
| Q1 25 | $47.5M | $454.6M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $47.3M | $489.3M | ||
| Q2 24 | $48.1M | $510.3M | ||
| Q1 24 | $48.2M | $577.3M |
总资产CSPILAB
| Q4 25 | $69.2M | — | ||
| Q3 25 | $71.2M | $539.6M | ||
| Q2 25 | $66.8M | $557.0M | ||
| Q1 25 | $67.1M | $579.6M | ||
| Q4 24 | $67.5M | — | ||
| Q3 24 | $69.4M | $681.5M | ||
| Q2 24 | $66.8M | $708.7M | ||
| Q1 24 | $64.2M | $777.7M |
负债/权益比CSPILAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-3.0M | $-23.1M |
| 自由现金流率自由现金流/营收 | -25.1% | -118.1% |
| 资本支出强度资本支出/营收 | 0.9% | 4.5% |
| 现金转化率经营现金流/净利润 | -32.04× | — |
| 过去12个月自由现金流最近4个季度 | $-2.8M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CSPILAB
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $1.9M | $-22.2M | ||
| Q2 25 | $-3.3M | $-20.7M | ||
| Q1 25 | $1.9M | $-30.3M | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $-1.5M | $-27.9M | ||
| Q2 24 | $2.4M | $-39.0M | ||
| Q1 24 | $1.7M | $-62.5M |
自由现金流CSPILAB
| Q4 25 | $-3.0M | — | ||
| Q3 25 | $1.7M | $-23.1M | ||
| Q2 25 | $-3.3M | $-22.6M | ||
| Q1 25 | $1.9M | $-35.3M | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $-1.5M | $-30.1M | ||
| Q2 24 | $2.4M | $-41.0M | ||
| Q1 24 | $1.6M | $-63.3M |
自由现金流率CSPILAB
| Q4 25 | -25.1% | — | ||
| Q3 25 | 11.5% | -118.1% | ||
| Q2 25 | -21.7% | -103.6% | ||
| Q1 25 | 14.5% | -86.6% | ||
| Q4 24 | 10.8% | — | ||
| Q3 24 | -11.7% | -136.4% | ||
| Q2 24 | 17.9% | -182.2% | ||
| Q1 24 | 11.9% | -138.9% |
资本支出强度CSPILAB
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.6% | 4.5% | ||
| Q2 25 | 0.4% | 8.7% | ||
| Q1 25 | 0.1% | 12.4% | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.1% | 10.2% | ||
| Q2 24 | 0.3% | 8.6% | ||
| Q1 24 | 0.1% | 1.7% |
现金转化率CSPILAB
| Q4 25 | -32.04× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.69× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.04× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSPI
| Products | $6.7M | 56% |
| Services | $5.3M | 44% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
